financetom
Business
financetom
/
Business
/
Former Swiss finance minister warns about size of enlarged UBS, newspaper says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Former Swiss finance minister warns about size of enlarged UBS, newspaper says
Jan 11, 2025 1:07 AM

ZURICH (Reuters) -UBS could be seen as being too big for Switzerland following its takeover of Credit Suisse, former Swiss Finance Minister Ueli Maurer said on Saturday, with measures needed to reduce the risks of the enlarged bank.

"If you look at the numbers alone and compare UBS with the Swiss economy, it is too big," Maurer told newspaper Tages-Anzeiger. "Therefore, the risk must be reduced."

At around $1.7 trillion, UBS's balance sheet is double the size of annual Swiss economic output, giving the bank exceptional weight for a major economy.

Should the bank fail, there are no local rivals left to absorb it, while the cost of nationalisation could severely damage public finances, experts have warned.

Reducing risks was primarily the responsibility of shareholders via their choice of board members, Maurer said.

"They must take responsibility, not the taxpayers in the end," said Maurer, who left office months before the final collapse of Credit Suisse in March 2023.

"Legislative measures must also be examined," said Maurer, who also defended himself after a recent parliamentary report raised questions about his actions as the Credit Suisse crisis worsened at the end of 2022.

The Swiss government last year laid out plans for tougher capital requirements for UBS and Switzerland's three other big banks in a bid to make the financial sector more robust after Credit Suisse's demise.

Details of the exact capital requirements are yet to emerge, but the possibility that UBS could be made to hold $15 billion to $25 billion in additional capital has met resistance from the bank.

Maurer said if the capital requirements were too high, Swiss banks would no longer be competitive and may look to be based elsewhere.

"For the Swiss economy with its many international multi-nationals, a large bank is a locational advantage," he said. "But risks must be minimized."

UBS declined to comment on the interview. The bank's CEO Sergio Ermotti earlier this month told Migros Magazine that UBS had enough capital to cover potential problems.

The bank supported many of the Swiss government's proposals to improve banking regulation, but they had to be targetted and proportionate, Ermotti told the magazine.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bloomin' Brands Names Michael Spanos CEO
Bloomin' Brands Names Michael Spanos CEO
Aug 26, 2024
09:13 AM EDT, 08/26/2024 (MT Newswires) -- Bloomin' Brands ( BLMN ) said Monday that it has named Michael Spanos as its chief executive officer, effective Sept. 3. Spanos, most recently the chief operating officer of Delta Air Lines (DAL), succeeds David Deno, who announced his retirement on May 7. ...
Golconda Gold's Q2 Revenue Increases QoQ
Golconda Gold's Q2 Revenue Increases QoQ
Aug 26, 2024
08:31 AM EDT, 08/26/2024 (MT Newswires) -- Golconda Gold ( GGGOF ) said Monday that its revenue increased 35% in the second quarter compared to the previous quarter. The company said it generated revenue of US$3.0 million from the sale of 1,721 payable ounces of gold at an operating cash cost of US$1,812 per payable ounce, compared to revenue of...
NRX Pharmaceuticals Secures Non-Binding Debt Financing Agreements for Ketamine Clinics
NRX Pharmaceuticals Secures Non-Binding Debt Financing Agreements for Ketamine Clinics
Aug 26, 2024
09:02 AM EDT, 08/26/2024 (MT Newswires) -- NRX Pharmaceuticals' ( NRXP ) HOPE Therapeutics subsidiary said Monday it has signed a non-binding agreement for $30 million in debt financing for its first interventional psychiatric clinics using the drug ketamine. The company also signed a non-binding agreement for $10 million worth of financing for five existing clinics in the western US....
Cigna to remove AbbVie's Humira from some drug reimbursement lists next year
Cigna to remove AbbVie's Humira from some drug reimbursement lists next year
Aug 26, 2024
Aug 26 (Reuters) - Cigna ( CI ) said on Monday it will remove AbbVie's ( ABBV ) blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead. Cigna ( CI ) said Boehringer Ingelheim's Cyltezo, Simlandi from Teva and Alvotech ( ALVO...
Copyright 2023-2026 - www.financetom.com All Rights Reserved